Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis

Abstract The Mayo-2018 smoldering multiple myeloma (SMM) risk score is used routinely in the clinical setting but has only been validated at diagnosis. In SMM patients, the progression risk decreases over time. However, the utility of applying risk stratification models after diagnosis is unknown. W...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alissa Visram, S. Vincent Rajkumar, Prashant Kapoor, Angela Dispenzieri, Martha Q. Lacy, Morie A. Gertz, Francis K. Buadi, Suzanne R. Hayman, David Dingli, Taxiarchis Kourelis, Wilson Gonsalves, Rahma Warsame, Eli Muchtar, Nelson Leung, Linda B. Baughn, Robert A. Kyle, Shaji Kumar
Formato:	article
Lenguaje:	EN
Publicado:	Nature Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/93d4ece315db4f62bf0683715cca31d3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:93d4ece315db4f62bf0683715cca31d3
record_format	dspace
spelling	oai:doaj.org-article:93d4ece315db4f62bf0683715cca31d32021-11-28T12:41:08ZAssessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis10.1038/s41408-021-00569-22044-5385https://doaj.org/article/93d4ece315db4f62bf0683715cca31d32021-11-01T00:00:00Zhttps://doi.org/10.1038/s41408-021-00569-2https://doaj.org/toc/2044-5385Abstract The Mayo-2018 smoldering multiple myeloma (SMM) risk score is used routinely in the clinical setting but has only been validated at diagnosis. In SMM patients, the progression risk decreases over time. However, the utility of applying risk stratification models after diagnosis is unknown. We retrospectively studied 704 SMM patients and applied the Mayo 2018 and IMWG-2020 risk stratification models at annual landmark timepoints up to 5 years post diagnosis. The Mayo-2018 and IMWG-2020 models reliably stratified patients based on progression risk when applied post diagnosis. The respective 2-year progression risk in Mayo-2018 high risk patients versus IMWG-2020 intermediate-high risk patients was 51% versus 62% at the 1-year landmark and 47% versus 45% at the 4-year landmark. We showed that patients categorized at Mayo-2018 high-risk at follow-up had a similar risk of progression if the baseline risk assessment was low-intermediate versus high-risk (HR 1.04, 95% CI 0.46–2.36, p = 0.931 at 5-year landmark). Patients migrating to a higher risk category during follow up had a higher progression risk compared to patients with stable/decreased risk categorization. Our findings support the use of these risk scores post-diagnosis and suggest that patients evolving to a high-risk category may benefit from early intervention therapeutic approaches.Alissa VisramS. Vincent RajkumarPrashant KapoorAngela DispenzieriMartha Q. LacyMorie A. GertzFrancis K. BuadiSuzanne R. HaymanDavid DingliTaxiarchis KourelisWilson GonsalvesRahma WarsameEli MuchtarNelson LeungLinda B. BaughnRobert A. KyleShaji KumarNature Publishing GrouparticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBlood Cancer Journal, Vol 11, Iss 11, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Alissa Visram S. Vincent Rajkumar Prashant Kapoor Angela Dispenzieri Martha Q. Lacy Morie A. Gertz Francis K. Buadi Suzanne R. Hayman David Dingli Taxiarchis Kourelis Wilson Gonsalves Rahma Warsame Eli Muchtar Nelson Leung Linda B. Baughn Robert A. Kyle Shaji Kumar Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis
description	Abstract The Mayo-2018 smoldering multiple myeloma (SMM) risk score is used routinely in the clinical setting but has only been validated at diagnosis. In SMM patients, the progression risk decreases over time. However, the utility of applying risk stratification models after diagnosis is unknown. We retrospectively studied 704 SMM patients and applied the Mayo 2018 and IMWG-2020 risk stratification models at annual landmark timepoints up to 5 years post diagnosis. The Mayo-2018 and IMWG-2020 models reliably stratified patients based on progression risk when applied post diagnosis. The respective 2-year progression risk in Mayo-2018 high risk patients versus IMWG-2020 intermediate-high risk patients was 51% versus 62% at the 1-year landmark and 47% versus 45% at the 4-year landmark. We showed that patients categorized at Mayo-2018 high-risk at follow-up had a similar risk of progression if the baseline risk assessment was low-intermediate versus high-risk (HR 1.04, 95% CI 0.46–2.36, p = 0.931 at 5-year landmark). Patients migrating to a higher risk category during follow up had a higher progression risk compared to patients with stable/decreased risk categorization. Our findings support the use of these risk scores post-diagnosis and suggest that patients evolving to a high-risk category may benefit from early intervention therapeutic approaches.
format	article
author	Alissa Visram S. Vincent Rajkumar Prashant Kapoor Angela Dispenzieri Martha Q. Lacy Morie A. Gertz Francis K. Buadi Suzanne R. Hayman David Dingli Taxiarchis Kourelis Wilson Gonsalves Rahma Warsame Eli Muchtar Nelson Leung Linda B. Baughn Robert A. Kyle Shaji Kumar
author_facet	Alissa Visram S. Vincent Rajkumar Prashant Kapoor Angela Dispenzieri Martha Q. Lacy Morie A. Gertz Francis K. Buadi Suzanne R. Hayman David Dingli Taxiarchis Kourelis Wilson Gonsalves Rahma Warsame Eli Muchtar Nelson Leung Linda B. Baughn Robert A. Kyle Shaji Kumar
author_sort	Alissa Visram
title	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis
title_short	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis
title_full	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis
title_fullStr	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis
title_full_unstemmed	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis
title_sort	assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis
publisher	Nature Publishing Group
publishDate	2021
url	https://doaj.org/article/93d4ece315db4f62bf0683715cca31d3
work_keys_str_mv	AT alissavisram assessingtheprognosticutilityofsmolderingmultiplemyelomariskstratificationscoresappliedseriallypostdiagnosis AT svincentrajkumar assessingtheprognosticutilityofsmolderingmultiplemyelomariskstratificationscoresappliedseriallypostdiagnosis AT prashantkapoor assessingtheprognosticutilityofsmolderingmultiplemyelomariskstratificationscoresappliedseriallypostdiagnosis AT angeladispenzieri assessingtheprognosticutilityofsmolderingmultiplemyelomariskstratificationscoresappliedseriallypostdiagnosis AT marthaqlacy assessingtheprognosticutilityofsmolderingmultiplemyelomariskstratificationscoresappliedseriallypostdiagnosis AT morieagertz assessingtheprognosticutilityofsmolderingmultiplemyelomariskstratificationscoresappliedseriallypostdiagnosis AT franciskbuadi assessingtheprognosticutilityofsmolderingmultiplemyelomariskstratificationscoresappliedseriallypostdiagnosis AT suzannerhayman assessingtheprognosticutilityofsmolderingmultiplemyelomariskstratificationscoresappliedseriallypostdiagnosis AT daviddingli assessingtheprognosticutilityofsmolderingmultiplemyelomariskstratificationscoresappliedseriallypostdiagnosis AT taxiarchiskourelis assessingtheprognosticutilityofsmolderingmultiplemyelomariskstratificationscoresappliedseriallypostdiagnosis AT wilsongonsalves assessingtheprognosticutilityofsmolderingmultiplemyelomariskstratificationscoresappliedseriallypostdiagnosis AT rahmawarsame assessingtheprognosticutilityofsmolderingmultiplemyelomariskstratificationscoresappliedseriallypostdiagnosis AT elimuchtar assessingtheprognosticutilityofsmolderingmultiplemyelomariskstratificationscoresappliedseriallypostdiagnosis AT nelsonleung assessingtheprognosticutilityofsmolderingmultiplemyelomariskstratificationscoresappliedseriallypostdiagnosis AT lindabbaughn assessingtheprognosticutilityofsmolderingmultiplemyelomariskstratificationscoresappliedseriallypostdiagnosis AT robertakyle assessingtheprognosticutilityofsmolderingmultiplemyelomariskstratificationscoresappliedseriallypostdiagnosis AT shajikumar assessingtheprognosticutilityofsmolderingmultiplemyelomariskstratificationscoresappliedseriallypostdiagnosis
_version_	1718407846409797632

Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis

Ejemplares similares